Management Team

Barry Dickman

Mr. Dickman joined the Board of Directors of GliaMed in June 2008 as the representative of Quantum Technology Partners. Currently Mr. Dickman is Chairman and CEO of the GliaMed and is the founder and managing general partner of Quantum. In addition to GliaMed, Mr. Dickman is responsible for Quantum’s investments in BiPar Sciences, an oncology company acquired by sanofi-aventis in 2Q2009; Vaxart, an oral vaccine delivery company; IMI Devices, developing an implantable device for treating blindness; Peri-Ness, a company developing a therapy for male infertility; and Corium, a transdermal delivery technology and product company.

Prior to founding Quantum, Mr. Dickman spent more than 25 years in technology and executive management positions. During this time he was founder and/or CEO of three technology companies which were acquired or went public. He also held senior management positions at Autodesk and Exxon Enterprise and has consulted for major corporations including News Corporation, HBO, DEC, Eastman Kodak and Adobe Systems.

John McCartney, Ph.D.

John McCartney joined GliaMed in April 2009 as Senior Director of Project Management to oversee GliaMed’s internal and external drug development activities. Dr. McCartney has over 20 years of drug development and project management experience, working previously with EPIX Pharmaceuticals, Point Therapeutics, Cystic Fibrosis Foundation Therapeutics and Curis/Creative BioMolecules. Dr. McCartney has led both preclinical and clinical development teams in multiple therapeutic areas, including orthopedic, urologic and vascular tissue repair, as well as oncology and pulmonary diseases. Dr. McCartney received his Ph.D. from Duke University and postdoctoral training at the Massachusetts Institute of Technology.